dm+d

Unassigned

New Medicines

Symptomatic neurogenic orthostatic hypotension (snOH)

Information

New molecular entity
Theravance Biopharma
Theravance Biopharma

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Sep 21Theravance announces it will make 270 staff redundant by the end of February, and switch its attention to respiratory disease pipeline after amprolexetine failed in the SEQUOIA trial. It will however complete the PIII REDWOOD study of ampreloxatine in nOH, and a PII trial of TD-1473 – a gut-selective JAK inhibitor – in ulcerative colitis [7].

Category

Noradrenaline reuptake inhibitor
OH is very common, especially in the elderly, due to a number of underlying problems with BP control. Causes include autonomic failure, Parkinson disease, diabetes [2].
Symptomatic neurogenic orthostatic hypotension (snOH)
Oral